Benzinga's Top Upgrades, Downgrades For September 5, 2017

Top Upgrades

• Argus upgraded Palo Alto Networks Inc PANW from Hold to Buy. Palo Alto shares declined 1.12 percent to $145.02 in pre-market trading.
• Analysts at Wedbush upgraded XOMA Corporation XOMA from Neutral to Outperform. XOMA shares gained 8.68 percent to $12.15 in pre-market trading.
• Wells Fargo upgraded Walt Disney Co DIS from Market Perform to Outperform. Disney shares rose 0.49 percent to $102.00 in pre-market trading.
• Susquehanna upgraded Lululemon Athletica inc. LULU from Neutral to Positive. Lululemon shares rose 0.42 percent to $61.95 in pre-market trading.
• SunTrust Robinson Humphrey upgraded Mack Cali Realty Corp CLI from Hold to Buy. Mack-Cali Realty shares climbed 2.16 percent to close at $23.38 on Friday.
• Analysts at Citigroup upgraded Liberty Media Corporation - Series A Liberty Formula One FWONA from Neutral to Buy. Liberty Formula One shares slipped 0.82 percent to close at $37.62 on Friday.
• Analysts at JP Morgan upgraded Alexion Pharmaceuticals, Inc. ALXN from Neutral to Overweight. Alexion Pharmaceuticals shares rose 0.76 percent to $145.18 in pre-market trading.
• MKM Partners upgraded Regal Entertainment Group RGC from Neutral to Buy. Regal Entertainment shares gained 4.87 percent to close at $15.49 on Friday.
• Citigroup upgraded Skyworks Solutions Inc SWKS from Sell to Buy. Skyworks shares gained 1.59 percent to $107.25 in pre-market trading.
• Keefe Bruyette & Woods upgraded NMI Holdings Inc NMIH from Market Perform to Outperform. NMIH shares rose 0.46 percent to close at $10.90 on Friday.

Top Downgrades

• Analysts at Wells Fargo downgraded Viacom, Inc. VIAB from Outperform to Market Perform. Viacom shares fell 0.49 percent to $28.38 in pre-market trading.
• Goldman Sachs downgraded AvalonBay Communities Inc AVB from Buy to Neutral. AvalonBay Communities shares rose 0.14 percent to close at $188.00 on Friday.
• Buckingham downgraded Rockwell Collins, Inc. COL from Buy to Neutral. Rockwell Collins shares rose 1.26 percent to $132.25 in pre-market trading.
• Deutsche Bank downgraded Allison Transmission Holdings Inc ALSN from Hold to Sell. Allison Transmission shares rose 0.89 percent to close at $35.04 on Friday.
• Janney Capital downgraded Calumet Specialty Products Partners, L.P CLMT from Buy to Neutral. Calumet Specialty shares fell 3.57 percent to $8.10 in pre-market trading.
• Vertical Research downgraded Rockwell Collins, Inc. COL from Buy to Hold. Rockwell Collins shares rose 1.26 percent to $132.25 in pre-market trading.

Top Initiations

• Analysts at Buckingham initiated coverage on Cummins Inc. CMI with a Buy rating. The price target for Cummins is set to $180. Cummins shares closed at $159.36 on Friday.
• Credit Suisse initiated coverage on Oracle Corporation ORCL with an Outperform rating. The price target for Oracle is set to $62. Oracle shares closed at $50.62 on Friday.
• Analysts at Guggenheim initiated coverage of CMS Energy Corporation CMS with a Neutral rating. The price target for CMS Energy is set to $48. CMS Energy shares closed at $48.42 on Friday.
• JMP Securities initiated coverage on Energy Recovery, Inc. ERII with a Market Outperform rating. The price target for Energy Recovery is set to $12. Energy Recovery shares closed at $6.55 on Friday.
• Analysts at Credit Suisse initiated coverage on VMware, Inc. VMW with an Outperform rating. The price target for VMware is set to $130. VMware shares closed at $107.48 on Friday.
• Analysts at Buckingham initiated coverage on Carlisle Companies, Inc. CSL with a Buy rating. The price target for Carlisle Companies is set to $115. Carlisle Companies shares closed at $94.72 on Friday.
• Guggenheim initiated coverage on Yogaworks Inc YOGA with a Buy rating. The price target for Yogaworks is set to $7. Yogaworks shares closed at $3.80 on Friday.
• H.C. Wainwright & Co. initiated coverage on Ligand Pharmaceuticals Inc. LGND with a Buy rating. The price target for Ligand Pharmaceuticals is set to $150. Ligand Pharmaceuticals shares closed at $128.93 on Friday.
• Needham initiated coverage on Zealand Pharma A/S ZEAL with a Buy rating. The price target for Zealand Pharma is set to $26. Zealand Pharma shares closed at $19.65 on Friday.